StockNews.AI
XGN
StockNews.AI
120 days

Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

1. Exagen will report Q1 2025 financial results on May 5, 2025. 2. CEO John Aballi and CFO Jeff Black will lead the conference call. 3. AVISE® CTD aids in diagnosing complex autoimmune conditions effectively. 4. Focus on research and innovation in autoimmune disease management is reiterated.

Earnings
+9.26%Current Return
VS
+2.57%S&P 500
$4.4304/21 04:15 PM EDTEvent Start
$4.8404/22 11:05 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

The announcement is routine; no immediate market-moving news is included.

How important is it?

Earnings announcements can be significant but results are unknown at this time.

Why Short Term?

Market reactions could occur post-earnings, affecting short-term trading behavior.

Related Companies

AMGNALNYDHRLABLSGEN
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com. A replay of the conference call will be available until Monday, May 19, 2025. Interested parties may access the replay by dialing 201-612-7415 (U.S.) or +1-877-660-6853 (international) using passcode 13753132. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes. About Exagen Inc. Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, visit Exagen.com or follow @ExagenInc on X. Contact:Ryan DouglasExagen Inc.ir@exagen.com760.560.1525

Related News